Hello everyone and welcome to Ad Barron's. I'm Andy Surwer. And welcome to our guest, Yvonne Green Street, CEO of Al-Nylem. Great to see you, Yvonne. Thank you for coming.

Lovely to be here, Andy. So part of your job is explaining what complex biopharma issues are to lay people and to investors.

So tell us what your company does.

Well, we believe that we have one of the most exciting companies in biotech.

We're founded on Nobel Prize-winning science of RNA interference, where essentially we can switch off the production of disease-causing proteins,

and therefore, based on this technology, we've been able to build a very rich pipeline

of medicines that are addressing some very important diseases.

So RNA-I, as the technology is called, are based on that kind of science, I guess, is the

way to characterize it.

Correct, yes.

What specifically, talk to us a little bit more about this, what specifically is the promise

of RNAI that is so unique?

So, you know, we believe that what we have with RNAI is actually a generational technology.

RNAI is an approach that can address any gene in the genome.

And because of this, it gives the technology huge potential to address a wide range of diseases.

And we've made tremendous progress over the last couple of decades since we were founded.

We now have brought forward five medicines from this technology in just four years.

And we have also built a pipeline of 15 clinical programs. And our plan is

actually to double the number of clinical programs by the end of 2025. So I think what's incredibly

impressive about the technology is just how prolific it has been in a very short space of time, based on the

science and on what are outsized probabilities of success in the industry. We have about a 10

times better success rate than industry averages. Recently, you filed for Food and Drug Administration to expand the approval of, I think it's

...